Cointime

Codagenix

company

About

Codagenix is a developer of live-attenuated viral vaccines intended to provide target antigens placed in an attenuated backbone virus.

  • 1 - 10

Highlights

Total Funding Amount
$100K
Funding Rounds
1
Investors
2

Details

Last Funding Type
Grant
Last Funding Money Raised
$100K
Industries
Biotechnology,Genetics
Founded date
Aug 1, 2011
Number Of Employee
1 - 10
Operating Status
Active

Codagenix is a developer of live-attenuated viral vaccines intended to provide target antigens placed in an attenuated backbone virus.The company's vaccines use Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain, enabling researchers to invent viral vaccine to treat influenza, dengue, polio, and other diseases. Codagenix has been developing a COVID-19 vaccine as well.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$100K
Codagenix has raised a total of $100K in funding over 2 rounds. Their latest funding was raised on Dec 16, 2014 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 16, 2014 Grant $100K 2 the Long Island Emerging technologies Fund (LIETF)
Accelerate Long Island 		— Detail

Investors

Number of Lead Investors
Number of Investors
2
2
Codagenix is funded by 2 investors. the Long Island Emerging technologies Fund (LIETF) and Accelerate Long Island are the most recent investors.
Investor Name Lead Investor Funding Round
the Long Island Emerging technologies Fund (LIETF) Yes Grant
Accelerate Long Island Yes Grant
Cointime
เนื้อหา
บริษัท